Amgen at neutral by Merrill

Amgen Inc. was rated at neutral by Merrill Lynch analyst Eric Ende after Roche's German/Swiss entities withdrew their motion to dismiss in the CERA patent infringement litigation due to several reasons. Merrill believes the judge won't dismiss the case and that Amgen has an opportunity to demonstrate infringement of its patents by CERA. Shares of the Thousand Oaks, Calif., biotechnology company were up 59 cents, or 0.88%, at $67.69 on volume of 11,158,137 shares versus the three-month running average of 8,743,890 shares. (Nasdaq: AMGN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.